Therapeutic Expertise
Dermatology & Cosmetic
Our dermatology team runs medical and aesthetic dermatology trials, from psoriasis and atopic dermatitis to acne, cutaneous lupus and skin cancers, using validated severity indices and standardised imaging.
Dermatology endpoints rely on validated severity scales (PASI, EASI, IGA) and increasingly on standardised photography and imaging. We calibrate assessors, standardise image capture and design endpoint strategies that satisfy FDA and EMA expectations for both therapeutic and cosmetic indications.
Addressing common pain points in dermatology & cosmetic clinical trials
Subjectivity in severity scoring
PASI, EASI and IGA scoring can vary between assessors.
We train and calibrate assessors and use standardised photography to reduce scoring variability.
Consistent lesion imaging
Photographic endpoints require reproducible lighting, positioning and capture.
We enforce standardised image acquisition and central review across sites.
Placebo/vehicle response
Topical vehicle effects can complicate signal detection.
We design vehicle-controlled protocols and blinding strategies that preserve assay sensitivity.
Resources
Dermatology & Cosmetic clinical trial resources
Psoriasis — Clinical Endpoints, Safety Concerns, and Therapeutic Innovations
Endpoint and safety considerations in psoriasis.
Advancements in Atopic Dermatitis
Trial design advances in atopic dermatitis.
Optimizing Clinical Trials for Acne Vulgaris
Design strategies for acne vulgaris trials.
Evidence & insights
Dermatology & Cosmetic white papers
Open-access reports from our physicians and data science teams — free, no sign-in.
Optimizing Clinical Trials for Acne Vulgaris
White paper · PDF ↗Advancements in Atopic Dermatitis
White paper · PDF ↗Overcoming Challenges in Cutaneous Lupus Erythematosus Clinical Trials
White paper · PDF ↗Advancing Melanoma Clinical Trials
White paper · PDF ↗Psoriasis - Clinical Endpoints, Safety Concerns, and Therapeutic Innovations
White paper · PDF ↗The iNGENū CRO difference
Australian expertise, direct FDA submission
We uniquely combine Australian expertise with direct FDA submission capabilities, offering a streamlined path for sponsors to achieve global approval. Trial data from Australia can be submitted directly to the FDA via our E-Gateway, eliminating the need for third-party intermediaries.
iNGENū takes a highly strategic and disciplined approach to clinical research, ensuring every dollar is directed toward generating meaningful outcomes — eliminating unnecessary costs while maintaining the highest scientific and regulatory standards across the Asia-Pacific region.
“We have been using iNGENū for a Phase 1, first-in-human trial of our investigational drug — medical writing, project management, clinical data management and full end-to-end execution and monitoring. We have been particularly impressed by the out-of-the-box creative solutions to speed up and reduce overheads during this clinical trial.”
Giles MossChief Executive Officer
Ready to discuss your Dermatology & Cosmetic clinical trial?
Talk to our team about how iNGENū CRO can accelerate your research.
Request a proposal